Probenecid sodium is used in combination with β-lactam antibiotics (including penicillins and cephalosporins) to form compound injectable formulations (such as powder for injection and lyophilized powder for injection), which are administered intravenously or via intravenous infusion. This combination effectively reduces the required dose of β-lactam antibiotics, thereby minimizing the development and spread of bacterial resistance caused by excessively high antibiotic doses, conserving antibiotic resources, and reducing antibiotic misuse. Additionally, probenecid sodium prolongs the half-life (t1/2) and increases the area under the curve (AUC) of β-lactam antibiotics. It also eliminates the hemolytic potential of probenecid sodium (or potassium), enhancing its safety profile in humans and enabling safe and effective intravenous administration as part of a novel combination formulation. Due to direct entry into systemic circulation, these compound injectables ensure complete absorption, rapid attainment of peak concentrations, swift onset of action, and enhanced therapeutic efficacy.